Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1956 1
1957 2
1964 1
1966 1
1968 2
1973 1
1974 2
1976 1
1977 1
1979 2
1980 3
1981 2
1982 1
1983 1
1984 1
1985 1
1986 1
1987 4
1988 3
1989 6
1990 5
1991 1
1993 4
1994 3
1995 1
1996 2
1997 1
1998 2
1999 2
2000 3
2002 5
2003 2
2004 1
2005 1
2006 2
2007 3
2008 1
2009 2
2010 5
2011 9
2012 7
2013 11
2014 6
2015 8
2016 6
2017 11
2018 4
2019 7
2020 4
2021 3
2022 2
2023 5
2024 9
2025 15
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah U, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Blood. 2024 Jul 25;144(4):402-407. doi: 10.1182/blood.2023023557. Blood. 2024. PMID: 38728378 Free PMC article.
The authors reply.
Firestone RL, Duby JJ. Firestone RL, et al. Crit Care Med. 2019 Sep;47(9):e793-e794. doi: 10.1097/CCM.0000000000003885. Crit Care Med. 2019. PMID: 31415330 No abstract available.
The authors reply.
Firestone RL, Duby JJ. Firestone RL, et al. Crit Care Med. 2019 Oct;47(10):e851. doi: 10.1097/CCM.0000000000003952. Crit Care Med. 2019. PMID: 31524712 No abstract available.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Vià MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV. Maura F, et al. Among authors: firestone r. J Clin Oncol. 2026 Jan 20;44(3):188-199. doi: 10.1200/JCO-25-01733. Epub 2025 Oct 8. J Clin Oncol. 2026. PMID: 41061199 Free PMC article.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. Firestone RS, et al. Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225. Blood Adv. 2024. PMID: 37878808 Free PMC article.
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.
Hultcrantz M, Derkach A, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, Shah UA, Tan CR, Chung DJ, Lahoud OB, Landau HJ, Scordo M, Shah GL, Nemirovsky D, Firestone RS, Akhlaghi T, Shekarkhand T, Giralt SA, Lesokhin AM, Usmani SZ. Hultcrantz M, et al. Among authors: firestone rs. Blood Neoplasia. 2025 Apr 16;2(3):100103. doi: 10.1016/j.bneo.2025.100103. eCollection 2025 Aug. Blood Neoplasia. 2025. PMID: 40575079 Free PMC article.
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: firestone rs. J Clin Oncol. 2025 Feb 10;43(5):498-504. doi: 10.1200/JCO-24-01785. Epub 2024 Dec 4. J Clin Oncol. 2025. PMID: 39631041 Clinical Trial.
Current use of CAR T cells to treat multiple myeloma.
Firestone RS, Mailankody S. Firestone RS, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):340-347. doi: 10.1182/hematology.2023000434. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066841 Free PMC article. Review.
183 results